Sanofi GCVRZ 深 沪
等待开盘 02-20 09:30:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi’s Real-World COPD Study on Dupilumab: What Investors Should Watch
Sanofi SA ($SNY) announced an update on their ongoing clinical study. The study...
02-18 00:30
FDA Grants Breakthrough Therapy Designation to Sanofi's Rilzabrutinib for wAIHA
FDA Grants Breakthrough Therapy Designation to Sanofi's Rilzabrutinib for wAIHA Sanofi SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib), a novel oral Bruton's tyrosine kinase inhibitor, for the treatment of warm autoi
02-17 22:34
BRIEF-Sanofi Appoints Manuela Buxo As Head Of Specialty Care
BRIEF-Sanofi Appoints Manuela Buxo As Head Of Specialty Care Feb 17 (Reuters) - Sanofi SA SASY.PA : ANNOUNCES LEADERSHIP EVOLUTION IN SPECIALTY CARE BUSINESS UNIT APPOINTMENT OF MANUELA BUXO AS HEAD OF SPECIALTY CARE, EFFECTIVE MARCH 1, 2026 BRIAN FOARD HAS DECIDED TO LEAVE COMPANY AS OF FEBRUARY 28
02-17 21:34
Sanofi announces leadership evolution in Specialty Care Business Unit
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, w...
02-17 21:30
Ocular drops after late-stage trial data for wet AMD therapy
Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular degener...
02-17 21:25
Sanofi’s Beyfortus shows hospitalization benefit across two RSV seasons
Sanofi (SNY) Monday said that a study published in The Lancet Infectious Diseases showed infants immunized with Beyfortus had 85.9% fewer RSV-related LRTI hospitalizations in the first season and 55.3...
02-17 17:07
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Positive results from the RELIEVE UCCD LTE study show duvakitug maintains durable efficacy over 44 weeks in UC and CD patients, with consistent safety and tolerability. Phase 3 programs are ongoing, reinforcing its potential as a best-in-class therapy for inflammatory bowel disease.
02-17 11:00
Changes to U.S. vaccine policy under RFK Jr. challenged in court
Several leading medical groups in the U.S. urged a federal judge on Friday to bar the CDC from holding its next vaccine advisory meeting and block the agency from implementing its recently upended imm...
02-15 00:20
Disc Medicine plunges on FDA Complete Response Letter for bitopertin
Disc Medicine (IRON) closed down ~22% Friday after receiving a Complete Response Letter from the US FDA for its application for bitopertin as a treatment for erythropoietic protoporphyria. The agency ...
02-14 05:59
Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.
02-13 21:23
